EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

A Randomized, Double‐Blind, Placebo‐Controlled, Phase 1 Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Single Vaccination of Ad26.RSV.preF‐Based Regimen in Japanese Adults Aged 60 Years and Older

Takashi Eto, Yusuke Okubo iD, Atsushi Momose, Hiroshi Tamura, Richuan Zheng, Benoit Callendret, Arangassery Rosemary Bastian, Christy A Comeaux

Influenza and Other Respiratory Viruses · 2024

DOI: 10.1111/irv.13336 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Influenza and Other Respiratory Viruses, 2024. Verfasst von Takashi Eto und 7 weiteren Autor:innen. Beteiligte Einrichtung: SOUSEIKAI Hakata Clinic, Fukuoka, Japan. Hauptthemen laut MEDLINE: Antibodies, Viral, Respiratory Syncytial Virus Infections, Respiratory Syncytial Virus Vaccines. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Janssen Pharmaceutical K.K.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Respiratory syncytial virus (RSV) is increasingly recognized as a significant cause of lower respiratory tract disease (LRTD) in older adults. The Ad26.RSV.preF/RSV preF protein vaccine demonstrated protective efficacy against RSV related LRTD in a Phase 2b study in the United States. Hence, Ad26.RSV.preF/RSV preF protein vaccine candidate was evaluated in the Japanese older adult population.

Methods

This Phase 1 study evaluated safety, reactogenicity, and immunogenicity of Ad26.RSV.preF/RSV preF protein vaccine at dose level of 1 × 10 11 vp/150 μg in Japanese healthy adult aged ≥60 years. The study included a screening Phase, vaccination, 28‐day follow up Phase, a 182‐day follow‐up period, and final visit on Day 183. A total of 36 participants were randomized in a 2:1 ratio to receive Ad26.RSV.preF/RSV preF protein vaccine ( n = 24) or placebo ( n = 12). After study intervention administration, the safety and immunogenicity analysis were performed as per planned schedule. Immune responses including virus‐neutralizing and preF‐specific binding antibodies were measured on Days 1, 15, 29, and 183.

Results

There were no deaths, SAEs, or AEs leading to discontinuation reported during the study. The Ad26.RSV.preF/RSV preF protein vaccine had acceptable safety and tolerability profile with no safety concern in Japanese older adults. The Ad26.RSV.preF/RSV preF protein vaccine induced RSV‐specific humoral immunity, with increase in antibody titers on Days 15 and 29 compared with baseline which was well maintained until Day 183.

Conclusions

A single dose of Ad26.RSV.preF/RSV preF protein vaccine had an acceptable safety and tolerability profile and induced RSV‐specific humoral immunity in Japanese healthy adults. Trial Registration NCT number: NCT04354480; Clinical Registry number: CR108768.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, ViralRespiratory Syncytial Virus InfectionsRespiratory Syncytial Virus VaccinesAgedAged, 80 and overFemaleHumansMaleMiddle AgedDouble-Blind MethodEast Asian PeopleImmunogenicity, VaccineJapan

Stichwörter der Autor:innen

adenovirus serotype 26respiratory syncytialrespiratory syncytial virus vaccinevirus adult vaccinationvirus fusion proteins

Substanzen

Antibodies, ViralRespiratory Syncytial Virus Vaccines

Autor:innen und Institutionen

  • SOUSEIKAI Hakata Clinic, Fukuoka, Japan.
  • Janssen Pharmaceutical K.K., Tokyo, Japan.
  • Janssen Vaccines & Prevention B.V., Leiden, The Netherlands.

ORCID-Profile: Yusuke Okubo

Förderung

  • Janssen Pharmaceutical K.K

Zitieren

APA

Eto, T., Okubo, Y., Momose, A., Tamura, H., Zheng, R., Callendret, B., Bastian, A. R., & Comeaux, C. A. (2024). A Randomized, Double‐Blind, Placebo‐Controlled, Phase 1 Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Single Vaccination of Ad26.RSV.preF‐Based Regimen in Japanese Adults Aged 60 Years and Older. Influenza and Other Respiratory Viruses. https://doi.org/10.1111/irv.13336

Vancouver

Eto T, Okubo Y, Momose A, Tamura H, Zheng R, Callendret B, et al. A Randomized, Double‐Blind, Placebo‐Controlled, Phase 1 Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Single Vaccination of Ad26.RSV.preF‐Based Regimen in Japanese Adults Aged 60 Years and Older. Influenza and Other Respiratory Viruses. 2024. doi:10.1111/irv.13336

BibTeX
@article{Eto2024,
  author = {Eto, Takashi and Okubo, Yusuke and Momose, Atsushi and Tamura, Hiroshi and Zheng, Richuan and Callendret, Benoit and Bastian, Arangassery Rosemary and Comeaux, Christy A},
  title = {A Randomized, Double‐Blind, Placebo‐Controlled, Phase 1 Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Single Vaccination of Ad26.RSV.preF‐Based Regimen in Japanese Adults Aged 60 Years and Older},
  journal = {Influenza and Other Respiratory Viruses},
  year = {2024},
  doi = {10.1111/irv.13336}
}
Kostenlos starten →